• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Nanobiotix S.A. ADR (NQ: NBTX )

    4.400 +0.240 (+5.77%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Nanobiotix S.A. ADR

    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Why is Trupanion (TRUP) Stock Down 32% Today?
    Trupanion (TRUP) stock is taking a beating on Friday after the pet medical insurance company released its earnings report for Q1 2023. 
    Via InvestorPlace
    12 Health Care Stocks Moving In Friday's Pre-Market Session
    Via Benzinga
    Why Is Galmed Pharmaceuticals (GLMD) Stock Up 37% Today?
    Galmed Pharmaceuticals (GLMD) stock is gaining on Friday after the company announced an investment agreement with OnKai. 
    Via InvestorPlace
    Why is Nanobiotix (NBTX) Stock Up 107% Today?
    Nanobiotix (NBTX) stock is taking off on Friday after the company revealed details about ongoing contract negotiations for NBTXR3. 
    Via InvestorPlace
    Why Carvana Shares Are Trading Higher By 35%; Here Are 20 Stocks Moving Premarket
    Gainers 
    Via Benzinga
    Why Are Nanobiotix Shares Plummeting Today?
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
    Good morning! We're diving into the biggest pre-market stock movers traders will want to keep an eye on for Friday morning! 
    Via InvestorPlace
    NANOBIOTIX Entering Final Contract Negotiations Following Agreement to Non-Binding Term Sheet for Development and Commercialization of NBTXR3 With a Major Global Pharmaceutical Company
    Company agreed to term sheet as of May 3, 2023 
    From Nanobiotix S.A.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    Why GE HealthCare Technologies Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Gainers 
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    NANOBIOTIX Provides Business Update and Reports Full Year 2022 Financial Results
    From Nanobiotix S.A.
    Via GlobeNewswire
    NANOBIOTIX to Provide Operational Update and Report Full Year 2022 Financial Results on April 24, 2023
    From Nanobiotix S.A.
    Via GlobeNewswire
    Voting Rights and Shares Capital of the Company
    From Nanobiotix S.A.
    Via GlobeNewswire
    Earnings Scheduled For April 24, 2023
    Companies Reporting Before The Bell • Dynex Cap (NYSE:DX) is estimated to report quarterly earnings at $0.17 per share on revenue of $6.99 million. 
    Via Benzinga
    Nanobiotix to Postpone Full Year 2022 Financial Results and Conference Call
    From Nanobiotix S.A.
    Via GlobeNewswire
    Nanobiotix to Provide Operational Update and Report Full Year 2022 Financial Results on March 28, 2023
    From Nanobiotix S.A.
    Via GlobeNewswire
    Voting Rights and Shares Capital of the Company
    In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) 
    From Nanobiotix S.A.
    Via GlobeNewswire
    Voting Rights and Shares Capital of the Company
    In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) 
    From Nanobiotix S.A.
    Via GlobeNewswire
    NANOBIOTIX Announces First Patient Randomized in the United States in Global Phase 3 Pivotal Trial Evaluating Radioenhancer NBTXR3 in Head and Neck Cancer
    From Nanobiotix S.A.
    Via GlobeNewswire
    NANOBIOTIX Announces Termination of Liquidity Contract and Publishes End of Contract Statement
    From Nanobiotix S.A.
    Via GlobeNewswire
    Voting Rights and Shares Capital of the Company
    From Nanobiotix S.A.
    Via GlobeNewswire
    NANOBIOTIX to Present at the 5th Annual Evercore ISI HealthCONx Conference
    From Nanobiotix S.A.
    Via GlobeNewswire
    NANOBIOTIX Announces Recommended Phase 2 Dose for NBTXR3 in Pancreatic Cancer
    From Nanobiotix S.A.
    Via GlobeNewswire
    Nanobiotix Posts Updated Data For Radiotherapy-Activated Cancer Therapy In Head & Neck Cancer Patients
    Via Benzinga
    NANOBIOTIX Reports Updated Phase 1 Anti-PD-1 Combination Data That May Support the Immune Stimulation Potential of Radioenhancer NBTXR3 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer
    Data to be discussed during Nanobiotix Q3 Earnings Call at 8:00AM EST 
    From Nanobiotix S.A.
    Via GlobeNewswire
    NANOBIOTIX Provides Third Quarter 2022 Operational and Financial Update
    From Nanobiotix S.A.
    Via GlobeNewswire
    NANOBIOTIX Voting Rights and Shares Capital of the Company
    From Nanobiotix S.A.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.